Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · Real-Time Price · USD
8.29
-0.70 (-7.79%)
At close: Aug 21, 2026, 4:00 PM EDT
8.29
0.00 (0.00%)
After-hours: Aug 21, 2026, 7:57 PM EDT
Iovance Biotherapeutics Revenue
Iovance Biotherapeutics had revenue of $99.31M in the quarter ending June 30, 2026, with 65.65% growth. This brings the company's revenue in the last twelve months to $324.97M, up 34.55% year-over-year. In the year 2025, Iovance Biotherapeutics had annual revenue of $263.50M with 60.60% growth.
Revenue (ttm)
$324.97M
Revenue Growth
+34.55%
P/S Ratio
11.56
Revenue / Employee
$333,302
Employees
975
Market Cap
3.76B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 263.50M | 99.43M | 60.60% |
| Dec 31, 2024 | 164.07M | 162.88M | 13,698.99% |
| Dec 31, 2023 | 1.19M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Legend Biotech | 1.27B |
| Telix Pharmaceuticals | 890.79M |
| IDEAYA Biosciences | 234.13M |
| Arcus Biosciences | 117.00M |
| AbCellera Biologics | 66.17M |
| Tango Therapeutics | 53.81M |
| uniQure | 18.67M |
| NewAmsterdam Pharma Company | 7.12M |
IOVA News
- 1 day ago - Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 days ago - Iovance Biotherapeutics price target raised to $7 from $4 at UBS - TheFly
- 5 days ago - Iovance Biotherapeutics price target raised to $11 from $10 at Mizuho - TheFly
- 5 days ago - Iovance Biotherapeutics put volume heavy and directionally bearish - TheFly
- 16 days ago - Iovance Biotherapeutics price target raised to $6 from $4 at Baird - TheFly
- 16 days ago - Iovance Biotherapeutics price target raised to $8 from $5 at Citizens - TheFly
- 16 days ago - Iovance Biotherapeutics price target raised to $13 from $11 at Barclays - TheFly
- 17 days ago - Iovance Biotherapeutics Earnings Call Transcript: Q2 2026 - Transcripts